

PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/067,790
				Filing Date	2/8/2002
				First Named Inventor	McCormick et al.
				Art Unit	1642
				Examiner Name	Christopher H. YAEN
Sheet	1	of	1	Attorney Docket Number	42254

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-6,403,371	06/11/2002	CONRAD et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SHU, et al., "Secretion of a single-gene-encoded immunoglobulin from myeloma cells", Proc. Natl. Acad. Sci. USA (1993) 90:7995-7999	

Examiner Signature		Date Considered	5/2/05
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/067,790	
			Filing Date	2/8/2002	
			First Named Inventor	McCormick et al.	
			Art Unit	1642	
Sheet	1	of	2	Examiner Name	Yaen, Christopher H.
				Attorney Docket Number	42254


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² - Number ⁴ - Kind Code ⁵ (if known)				
		WO 94/08008	4/14/1994	HAWKINS, et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BENVENUTI and BURRONE, "Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V _L /V _H determinants", <i>Gene Therapy</i> (2001) 8:1555-1561	
		CASPAR, et al., "Idiotypic vaccines for non-hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations", <i>Blood</i> (1997) 90(9):3699-3706	
		DE GRUIJL and CURIEL, "Cancer vaccine strategies get bigger and better", <i>Nature Medicine</i> (1999) 5(10):1124-1125	
		DONNELLY, "Cancer vaccine targets leukemia", <i>Nature Medicine</i> (2003) 9(11):1354-1356	
		EVANS and KAYE, "Vaccine therapy for cancer - fact or fiction?" <i>Q J Med.</i> (1999) 92:299-307	
		FITCHEN, et al., "Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response", <i>Vaccine</i> (1995) 13:1051-1057	
		GIRARD, et al., "Methodes d'etudes des virus", <i>Virologie Moleculaire</i> (1989), Chapter 2, pp. 61-65	
		HAKIM, et al., "A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines", <i>J. Immun.</i> (1996) 157(12):5503-5511	
		HENNECKE, et al., "Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology", <i>Protein Engineering</i> (1998) 11(5):405-410	
		HSU, et al., "Tumor-Specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial", <i>Blood</i> (1997) 89(9):3129-3135	
		JERALA, et al., "Improved expression and evaluation of polyethyleneimine precipitation in isolation of recombinant cysteine proteinase inhibitor Stefin B", <i>Protein Expression and Purification</i> (1994) 5:65-69	

Examiner Signature		Date Considered	5/2/05
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/067,790
				Filing Date	2/8/2002
				First Named Inventor	McCormick et al.
				Art Unit	1642
				Examiner Name	Yaen, Christopher H.
Sheet	2	of	2	Attorney Docket Number	42254


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KING, et al., "DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma", <i>Nature Medicine</i> (1998) 4(11):1281-1286	
		LANGEVELD, et al., "Effective induction of neutralizing antibodies with the amino terminus of VP2 of canine parvovirus as a synthetic peptide", <i>Vaccine</i> (1994) 12:1473-1480	
		STEMMER, et al., "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR", <i>Biotech.</i> (1993) 14(2):256-265	
		TANG, et al., "Selection of linkers for a catalytic single-chain antibody using phage display technology" (1996) 271(26):15682-15686	
		TAVLADORAKI, et al., "A single-chain antibody fragment is functionally expressed in the cytoplasm of both <i>Escherichia coli</i> and transgenic plants", <i>European J. Biochem.</i> (1999) 262(2):617-624	
		TURNER, et al., "Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology", <i>J. Immun. Methods</i> (1997) 205(1):43-54	

Examiner Signature		Date Considered	5/2/05
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.



This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 <p>Substitute for form 1449A/PTO</p> <p>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/067,790
		Filing Date	2/8/2002
		First Named Inventor	McCormick et al.
		Art Unit	1642
		Examiner Name	
Sheet 1 of 1		Attorney Docket Number	42254

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FIEDLER, et al., "Optimization of scFv antibody production in transgenic plants", <i>Immunotechnology</i> (1997), 3:205-216	
		VAQUERO, et al., "Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves", <i>Proc. Natl. Acad. Sci.</i> (1999), 96:11128-11133	

Examiner Signature		Date Considered	5/2/05
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 42254	SERIAL NO. Div of 09/522,900
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT McCormick et al.	GROUP TBA
		FILING DATE 8 February 2002	

1-971 U.S. PTO
10/067790

02/08/02

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>SA</i>	5 8 6 9 2 8 7	9 Feb 1999	Price et al.			
<i>SA</i>	5 2 4 0 8 4 5	31 Aug 1993	Fujii, deceased et al.			
<i>SA</i>	5 5 4 1 3 0 9	30 Jul 1996	Prasher			
<i>SA</i>	4 7 6 0 0 2 5	26 Jul 1998	Estell et al.			
<i>SA</i>	5 5 9 5 8 8 7	21 Jan 1997	Coolidge et al.			
<i>SA</i>	5 6 5 6 4 5 6	12 Aug 1997	Stout et al.			
<i>SA</i>	4 7 8 2 1 3 7	1 Nov 1988	Hopp et al.			
<i>SA</i>	5 6 0 8 0 3 9	4 Mar 1997	Pastan			
<i>SA</i>	5 9 3 9 4 5 5	17 Aug 1999	Rephaeli			
<i>SA</i>	5 9 1 2 1 7 2	15 Jun 1999	Eshhar et al.			
<i>SA</i>	5 9 0 6 9 3 6	25 May 1999	Eshhar et al.			
<i>SA</i>	5 8 8 5 7 9 3	23 Mar 1999	Griffiths et al.			
<i>SA</i>	5 7 9 2 6 0 4	11 Aug 1998	Jefferies et al.			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

<i>SA</i>	Pharmaceutical Biotechnology, "Vaccine Design: The Subunit and Adjuvant Approach." Powell & Newman, Eds. Vol. 6 pp. 389-412, (1995).
<i>SA</i>	Proc. Natl. Acad. Sci. USA, McCormick et al., "Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants." Vol. 96, pp. 703-708, (1999).

EXAMINER <i>SA</i>	DATE CONSIDERED <i>5/2/05</i>
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

[illegible]